Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.42 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22191365 | 0.87 | GRM5 (0.45) | PDE3BPDE3AKDM4EGRIA1CACNG8 | |
| SCHEMBL22190814 | 0.87 | GRIA1 (0.48) | MAPTALDH1A1PDE3BPDE3AGAA | |
| SCHEMBL22191685 | 0.86 | RET (0.51) | MAPTALDH1A1PDE3BPDE3AHDAC3 | |
| SCHEMBL22191405 | 0.84 | HDAC3 (0.47) | MAPTALDH1A1PDE3BPDE3AHDAC3 | |
| SCHEMBL22190998 | 0.83 | GAA (0.47) | MAPTALDH1A1PDE3BPDE3AGAA | |
| SCHEMBL22190930 | 0.80 | AURKB (0.44) | MAPTALDH1A1PDE3BPDE3AGAA | |
| SCHEMBL22191468 | 0.79 | HDAC3 (0.49) | MAPTPDE3BPDE3AGAAHDAC3 | |
| SCHEMBL22191259 | 0.78 | USP2 (0.50) | ALDH1A1GRIA1CACNG8 | |
| SCHEMBL14937159 | 0.77 | MAPT (0.40) | MAPTALDH1A1PDE3BPDE3AGAA | |
| SCHEMBL22191321 | 0.76 | DYRK1A (0.48) | MAPTALDH1A1PDE3BPDE3AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220064146-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-03 | — | — | US | disclosed |
| EP-3906028-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | Icahn School of Medicine at Mount Sinai (US) | 2021-11-10 | — | — | EP | disclosed |
| CN-113543783-A | Kinase inhibitor compounds and compositions and methods of use | 西奈山伊坎医学院 | 2021-10-22 | — | — | CN | disclosed |
| WO-2020142486-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2020-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220064146-A1 | KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE | CSNK1A1, MAP3K20, CSNK1G3 | MAPT 1414/4885ALDH1A1 4521/4885PDE3B 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.